Definium Reports $77.1M Q1 Net Loss, Driven by Increased R&D for Phase 3 Trials
DFTX has more than doubled off its 52-week low of $6.03.
Summary
Definium Therapeutics reported a Q1 net loss of $77.1 million, or $0.71 per share, which widened compared to the prior year. This increased loss was primarily due to higher R&D costs associated with advancing its DT120 ODT clinical trials, including completing enrollment in key Phase 3 studies. The company reaffirmed its cash and investments of $373.4 million are sufficient to fund operations into 2028, consistent with the capital raise reported in its last 10-K. While the widening net loss is a negative financial outcome, the underlying cause—increased investment in late-stage clinical trials—is a strategic move for a biopharma company. The reaffirmed cash runway provides stability, mitigating immediate concerns about liquidity despite the current unprofitability. Investors will be watching for topline data from three Phase 3 DT120 ODT studies expected by the end of Q3 2026, and the planned initiation of a Phase 3 PTSD study in 2027.
At the time of this announcement, DFTX was trading at $22.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $6.03 to $26.25. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.